Subscribe
22 October 2024NewsAmericasMarisa Woutersen

10x Genomics counsel: ‘Winning cases is a top priority’

10x Genomics senior director of IP and litigation shares her team's tasks, how she’s handling UPC litigation, and why sometimes she wants a ‘gut answer’ from externals, finds Marisa Woutersen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Moderna wins reprieve in COVID-19 vaccine dispute
3 October 2024   Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.
Biotechnology
BlueAllele says rival gained $100m from Regeneron deal using patented tech
9 July 2024   Minnesota-based biotech firm says Intellia used its patented gene editing innovations | Regeneron paid Intellia $100m for R&D that infringed three patents, alleges BlueAllele.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Americas
Moderna wins reprieve in COVID-19 vaccine dispute
3 October 2024   Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.
Biotechnology
BlueAllele says rival gained $100m from Regeneron deal using patented tech
9 July 2024   Minnesota-based biotech firm says Intellia used its patented gene editing innovations | Regeneron paid Intellia $100m for R&D that infringed three patents, alleges BlueAllele.

More on this story

Americas
Moderna wins reprieve in COVID-19 vaccine dispute
3 October 2024   Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.
Biotechnology
BlueAllele says rival gained $100m from Regeneron deal using patented tech
9 July 2024   Minnesota-based biotech firm says Intellia used its patented gene editing innovations | Regeneron paid Intellia $100m for R&D that infringed three patents, alleges BlueAllele.

More features

Barnes & Thornburg reveals five new IP leaders
Former PTAB judge joins Sterne Kessler
GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires